Source link : https://www.newshealth.biz/health-news/blinatumomab-plus-chemotherapy-new-standard-for-children-with-b-cell-all/
The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy significantly improved disease-free survival for children with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). In this exclusive MedPage Today video, Rachel Rau, MD, of the University of Washington and […]
Author : News Health
Publish date : 2024-12-30 16:10:00
Copyright for syndicated content belongs to the linked Source.